IL148372A0 - Cationic liposome delivery of taxanes to angiogenic blood vessels - Google Patents

Cationic liposome delivery of taxanes to angiogenic blood vessels

Info

Publication number
IL148372A0
IL148372A0 IL14837200A IL14837200A IL148372A0 IL 148372 A0 IL148372 A0 IL 148372A0 IL 14837200 A IL14837200 A IL 14837200A IL 14837200 A IL14837200 A IL 14837200A IL 148372 A0 IL148372 A0 IL 148372A0
Authority
IL
Israel
Prior art keywords
taxanes
blood vessels
cationic liposome
liposome delivery
angiogenic blood
Prior art date
Application number
IL14837200A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL148372A0 publication Critical patent/IL148372A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL14837200A 1999-09-09 2000-09-08 Cationic liposome delivery of taxanes to angiogenic blood vessels IL148372A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39297699A 1999-09-09 1999-09-09
PCT/US2000/024579 WO2001017508A1 (en) 1999-09-09 2000-09-08 Cationic liposome delivery of taxanes to angiogenic blood vessels

Publications (1)

Publication Number Publication Date
IL148372A0 true IL148372A0 (en) 2002-09-12

Family

ID=23552795

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14837200A IL148372A0 (en) 1999-09-09 2000-09-08 Cationic liposome delivery of taxanes to angiogenic blood vessels
IL148372A IL148372A (en) 1999-09-09 2002-02-25 Transition of Texans by cationic liposome to angiogenic blood vessels

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148372A IL148372A (en) 1999-09-09 2002-02-25 Transition of Texans by cationic liposome to angiogenic blood vessels

Country Status (21)

Country Link
US (1) US20100226970A1 (es)
EP (1) EP1210065B1 (es)
JP (2) JP4848113B2 (es)
KR (1) KR100591767B1 (es)
CN (1) CN1235567C (es)
AT (1) ATE324867T1 (es)
AU (1) AU782714B2 (es)
BR (1) BR0013866A (es)
CA (1) CA2383412C (es)
CZ (1) CZ2002850A3 (es)
DE (1) DE60027730T2 (es)
EA (1) EA005923B1 (es)
EE (1) EE200200127A (es)
ES (1) ES2258471T3 (es)
HK (1) HK1046506B (es)
HU (1) HUP0202669A3 (es)
IL (2) IL148372A0 (es)
MX (1) MXPA02002579A (es)
PL (1) PL203128B1 (es)
WO (1) WO2001017508A1 (es)
ZA (1) ZA200201555B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301835A2 (hu) * 2000-05-03 2003-09-29 Mbt Munich Biotechnology Ag Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva
JP4778679B2 (ja) * 2001-10-03 2011-09-21 セレーター ファーマシューティカルズ インコーポレイテッド 併用薬剤を送達するための組成物
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2003234670B2 (en) 2002-05-24 2010-06-10 Angiotech International Ag Compositions and methods for coating medical implants
CA2492080A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
WO2004002468A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Method of producing a cationic liposomal preparation comprising a lipophilic compound
EP1374864A1 (en) * 2002-06-26 2004-01-02 Munich Biotech AG Amphiphilic taxane compositions
US9044381B2 (en) 2003-06-24 2015-06-02 Baxter International Inc. Method for delivering drugs to the brain
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
ES2574231T3 (es) * 2003-10-15 2016-06-16 Syncore Biotechnology Co., Ltd Uso de liposomas catiónicos que comprenden paclitaxel
CA2559889A1 (en) 2004-01-16 2005-08-25 Barnes-Jewish Hospital Targeted atherosclerosis treatment
WO2006117220A2 (en) 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
EP3056196A1 (en) 2006-03-22 2016-08-17 SynCore Biotechnology CO., LTD Treatment of triple receptor negative breast cancer
CN101965195A (zh) 2008-03-05 2011-02-02 巴克斯特国际公司 用于药物投送的组合物和方法
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US9706903B2 (en) 2009-06-18 2017-07-18 Endochoice, Inc. Multiple viewing elements endoscope system with modular imaging units
DE102009032658A1 (de) * 2009-07-09 2011-01-13 Forschungszentrum Jülich GmbH Mischung amphipathischer Moleküle und Verfahren zur Zellmembranmodifikation durch Fusion
KR101007925B1 (ko) * 2009-10-07 2011-01-14 건일제약 주식회사 경구용 지질 나노입자 및 그의 제조방법
SG11201903326RA (en) * 2016-10-28 2019-05-30 Servier Lab Liposomal formulation for use in the treatment of cancer
KR102250123B1 (ko) 2019-11-25 2021-05-10 주식회사 현대케피코 무단 변속기의 제한 목표 기어비 학습 방법
KR102261482B1 (ko) 2019-12-10 2021-06-07 주식회사 현대케피코 무단 변속기의 킥다운 시프트 직후 구동 풀리 제어 압력 보정 방법 및 장치

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0470569B1 (en) * 1990-08-08 1995-11-22 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis inhibiting substance
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
ATE194767T1 (de) * 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
EP0703909B1 (en) * 1993-06-11 2000-04-26 PHARMACIA & UPJOHN COMPANY Delta 6,7 -taxols antineoplastic use and pharmaceutical compositions containing them
EP1118325B2 (en) * 1993-07-29 2010-01-06 The United States of America, represented by the Secretary, Department of Health and Human Services Use of Paclitaxel and its derivatives in the manufacture of a medicament for treating restenosis.
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5641755A (en) * 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
DE19605274A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
CA2250295C (en) * 1996-03-12 2008-12-30 Pg-Txl Company L.P. Water soluble paclitaxel prodrugs
US5935937A (en) * 1996-06-19 1999-08-10 Fox Chase Cancer Center Compositions and methods for inducing apoptosis
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
AU5646300A (en) * 1999-02-10 2000-08-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of stimulating angiogenesis
WO2003037337A1 (en) * 2001-10-30 2003-05-08 Novartis Ag Depot formulations of iloperidone and a star polymer

Also Published As

Publication number Publication date
PL354721A1 (en) 2004-02-09
HK1046506A1 (en) 2003-01-17
PL203128B1 (pl) 2009-08-31
HK1046506B (zh) 2006-08-25
KR100591767B1 (ko) 2006-06-23
CZ2002850A3 (cs) 2003-04-16
EP1210065A1 (en) 2002-06-05
AU7122900A (en) 2001-04-10
DE60027730T2 (de) 2007-03-29
DE60027730D1 (de) 2006-06-08
CA2383412A1 (en) 2001-03-15
US20100226970A1 (en) 2010-09-09
KR20030038530A (ko) 2003-05-16
CA2383412C (en) 2010-02-02
CN1378443A (zh) 2002-11-06
EP1210065B1 (en) 2006-05-03
ATE324867T1 (de) 2006-06-15
WO2001017508A9 (en) 2002-10-03
ES2258471T3 (es) 2006-09-01
IL148372A (en) 2007-09-20
HUP0202669A3 (en) 2004-06-28
BR0013866A (pt) 2002-05-14
JP4848113B2 (ja) 2011-12-28
EA200200229A1 (ru) 2003-06-26
JP2003514768A (ja) 2003-04-22
AU782714B2 (en) 2005-08-25
EA005923B1 (ru) 2005-08-25
EE200200127A (et) 2003-04-15
ZA200201555B (en) 2003-04-30
CN1235567C (zh) 2006-01-11
JP2010280667A (ja) 2010-12-16
EP1210065A4 (en) 2004-04-28
WO2001017508A1 (en) 2001-03-15
HUP0202669A2 (hu) 2004-05-28
MXPA02002579A (es) 2003-10-14

Similar Documents

Publication Publication Date Title
IL148372A0 (en) Cationic liposome delivery of taxanes to angiogenic blood vessels
IL171355A (en) Cationic lipid compositions targeting angiogenic endothelial cells
Gibot et al. Antitumor drug delivery in multicellular spheroids by electropermeabilization
DE69708919D1 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
Sugahara et al. The cytotoxic effect of Eucheuma serra agglutinin (ESA) on cancer cells and its application to molecular probe for drug delivery system using lipid vesicles
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
ATE462468T1 (de) Vorrichtungen zur vergrösserten penetration von mikronadeln in biologischen hautschichten
WO2005051351A3 (en) Gene delivery mediated by liposome-dna complex with cleavable peg surface modification
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
MX9801264A (es) Control de la expresion del gen de cd44 para uso terapeutico.
AU2002217760A1 (en) Targeting drug/gene carriers to irradiated tissue
WO2004113497A3 (en) Gene delivery to tumors
ATE419833T1 (de) Modulares zielgerichtetes liposomales verabreichungssytem
CN203360445U (zh) 超声微泡介导转染辅助装置
NZ516777A (en) Method for delivery of therapeutic agents, particularly nucleic acids, using a solution of dextrin
DE60035687D1 (de) Bipolare lipide und ihre verwendung zum transport bioaktiver substanzen
IT246835Y1 (it) Struttura di supporto per contenitori particolarmente di prodotti incarta , in foglio e simili
Straubinger LIPOSOME-CELL INTERACTION: MECHANISM OF LIPOSOME INTERNALIZATION AND INTRACELLULAR FATE OF LIPOSOME CONTENTS (ENDOCYTOSIS, DRUG CARRIER, CANCER CHEMOTHERAPY, MICROINJECTION, TRANSFECTION SYSTEM)
TH33765A (th) ตัวกระตุ้นฤทธิ์เอนไซม์นิวคลีเอสของเซลล์มะเร็ง

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed